Sonia Meynier, PhD

Dr. Sonia Meynier joined Labcorp Drug Development in 2021 as a staff scientist in the targeted cell isolation department. In her role, Sonia is responsible for improving and bringing new techniques for cell isolation, defining and analyzing the validations for new procedures, reviewing and providing pricing for new studies and collaborating with the lab to highlight improvements that increase product quality.

Before joining Labcorp, Sonia worked as a postdoctoral research fellow at Institut Image (France), where she studied the characterization and evolution of juvenile myelomonocytic leukemia by studying the RAS and CBL mutations and the associated signaling pathways. During the COVID-19 period, she participated in the characterization of COVID-19 pediatric patients with a severe myocarditis. She received her doctorate from the Geneva University Hospital (Switzerland), where she focused her research on the role of PAR-4 in ovarian cancer.